Apr. 1 at 9:44 AM
$SLRX Q4 '25 Earnings Results & Recap
Salarius Pharmaceuticals Inc expects to file an IND application for its pan-Coronavirus peptide conjugate in the first half of 2027 and anticipates receiving a final
$600,000 grant tranche in the first half of 2026.